City Holding Co. Purchases 1,101 Shares of Thermo Fisher Scientific Inc. $TMO

City Holding Co. grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.8% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 5,375 shares of the medical research company’s stock after buying an additional 1,101 shares during the quarter. City Holding Co.’s holdings in Thermo Fisher Scientific were worth $2,695,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of TMO. Orrstown Financial Services Inc. increased its position in Thermo Fisher Scientific by 2.2% during the second quarter. Orrstown Financial Services Inc. now owns 1,651 shares of the medical research company’s stock worth $828,000 after acquiring an additional 36 shares during the period. Community Financial Services Group LLC grew its position in shares of Thermo Fisher Scientific by 18.1% during the 2nd quarter. Community Financial Services Group LLC now owns 814 shares of the medical research company’s stock worth $418,000 after purchasing an additional 125 shares in the last quarter. Fulton Bank N.A. increased its holdings in shares of Thermo Fisher Scientific by 1.4% during the second quarter. Fulton Bank N.A. now owns 6,697 shares of the medical research company’s stock worth $3,358,000 after purchasing an additional 95 shares during the period. Harrell Investment Partners LLC raised its position in shares of Thermo Fisher Scientific by 1.5% in the second quarter. Harrell Investment Partners LLC now owns 1,739 shares of the medical research company’s stock valued at $872,000 after buying an additional 25 shares in the last quarter. Finally, Sapient Capital LLC boosted its stake in shares of Thermo Fisher Scientific by 11.5% in the second quarter. Sapient Capital LLC now owns 885 shares of the medical research company’s stock valued at $444,000 after buying an additional 91 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $71,191,194.75. This represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,553 shares of company stock valued at $15,343,589 over the last 90 days. 0.33% of the stock is owned by corporate insiders.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher received FDA clearance for a multiple myeloma testing platform, strengthening its position in clinical diagnostics and potentially expanding adoption among hospitals, laboratories, and pharmaceutical companies. The development reinforces the company’s broader growth strategy in precision medicine. How Investors Are Reacting To Thermo Fisher Scientific New FDA-Cleared Multiple Myeloma Platform
• Positive Sentiment: Thermo Fisher expects its India customer base to grow 15% to 20% over the next five years as biopharmaceutical research and manufacturing expand in the country. The outlook points to a meaningful long-term international growth opportunity for the company’s instruments, services, and bioproduction businesses. Thermo Fisher Eyes India Customer Growth
• Positive Sentiment: Comparative coverage emphasizes Thermo Fisher’s stronger recent positioning in a potential recovery of pharmaceutical and biotechnology research spending. The company exceeded second-quarter expectations, raised guidance, and reported broad-based demand improvement, factors that can support investor confidence relative to peers such as Danaher. Thermo Fisher vs. Danaher
• Neutral Sentiment: Articles comparing Thermo Fisher with Abbott and Azenta frame the investment decision around diversification, valuation, and exposure to a life-sciences spending recovery. These are investor-perspective pieces rather than new company announcements, so their direct effect on TMO is limited. Abbott vs. Thermo Fisher Thermo Fisher and Azenta Comparison
• Negative Sentiment: CEO Marc Casper and Chief Accounting Officer Joseph Holmes sold shares. Both transactions were disclosed as part of planned trading activity, reducing the likelihood that the sales signal deteriorating business prospects, but insider selling can still create modest short-term sentiment pressure. Thermo Fisher Insider Trading Filing

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TMO. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Barclays increased their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Up 0.8%

Shares of NYSE TMO opened at $598.68 on Tuesday. The company has a 50 day simple moving average of $519.74 and a 200 day simple moving average of $509.70. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm has a market cap of $221.36 billion, a PE ratio of 32.20, a price-to-earnings-growth ratio of 2.42 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.